Kyntra Bio Inc. Common Stock (KYNB)

About KYNB

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

34

Website

www.kyntrabio.com

Fundamentals

1-day range

$6.95$7.41

Market cap

$27.37M

P/E (trailing)

—

P/E (forward)

-0.50

EPS (trailing)

$-7.64

Dividend yield

—

Beta

—

Avg. volume

17.9K

Forecasts

2 analyst ratings

Kyntra Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KYNB

  Kyntra Bio Inc. Common Stock

  $8.02

  ▲ 1.26%
  Market cap $27.37MP/E —
  $6.32$12.6
• ABVC

  ABVC BioPharma Inc. Common Stock

  $0.8251

  ▲ 3.66%
  Market cap $27.62MP/E —
  $0.7069$3.4
• NIKI

  Niki BioSolutions Inc. Common Stock

  $6.9

  ▼ 8.49%
  Market cap $28.45MP/E —
  $7.01$12.24
• RMTI

  Rockwell Medical Inc. Common Stock

  $8.22

  ▲ 6.06%
  Market cap $28.54MP/E —
  $4.89$21
• BTAI

  BioXcel Therapeutics Inc. Common Stock

  $0.1824

  ▼ 74.63%
  Market cap $26.17MP/E —
  $0.1569$4.29
• BCTX

  BriaCell Therapeutics Corp. Common Shares

  $3.73

  ▲ 0.54%
  Market cap $29.23MP/E —
  $3.68$20.4
• ACTU

  Actuate Therapeutics Inc. Common stock

  $1.67

  ▼ 1.18%
  Market cap $25.36MP/E —
  $0.9$9.22

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Kyntra Bio, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/16/2026
• Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/14/2026
• UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate
  Benzinga · 8/13/2026
• Kyntra Bio Q2 2026 Earnings Call: Complete Transcript
  Benzinga · 8/13/2026

• Maykin Ho · June 12, 2026 · Grant

  7.0K
• James A. Schoeneck · June 12, 2026 · Grant

  7.0K
• Michael Kauffman · June 12, 2026 · Grant

  7.0K
• EDWARDS JEFFREY L · June 12, 2026 · Grant

  7.0K
• David DeLucia · June 6, 2026 · Tax Withholding

  52 @ $6.71
• Thane Wettig · June 6, 2026 · Tax Withholding

  198 @ $6.71
• Thane Wettig · May 14, 2026 · Buy

  2.8K @ $7.09
• David DeLucia · March 6, 2026 · Tax Withholding

  60 @ $6.84
• Thane Wettig · March 6, 2026 · Tax Withholding

  277 @ $6.84

Institutional Ownership

March 31, 2026

Total shares held

1.10M

Total value held

$6.73M

Institutional holders

30